ERBB2 and breast carcinoma: Our first time finding provides support to the role of p53 status as effect modifier of the association between pre-treatment fasting glucose and treatment outcomes in a well specified molecular subtype of breast cancer, i.e., HER2 positive, in non diabetic patients treated with trastuzumab.